View in EDS

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Authors: Folegatti, Pedro M (AUTHOR), Ewer, Katie J (AUTHOR), Aley, Parvinder K (AUTHOR), Angus, Brian (AUTHOR), Becker, Stephan (AUTHOR), Belij-Rammerstorfer, Sandra (AUTHOR), Bellamy, Duncan (AUTHOR), Bibi, Sagida (AUTHOR), Bittaye, Mustapha (AUTHOR), Clutterbuck, Elizabeth A (AUTHOR), Dold, Christina (AUTHOR), Faust, Saul N (AUTHOR), Finn, Adam (AUTHOR), Flaxman, Amy L (AUTHOR), Hallis, Bassam (AUTHOR), Heath, Paul (AUTHOR), Jenkin, Daniel (AUTHOR), Lazarus, Rajeka (AUTHOR), Makinson, Rebecca (AUTHOR), Minassian, Angela M (AUTHOR)
Source: Lancet. 8/15/2020, Vol. 396 Issue 10249, p467-478. 12p.
Subjects: SARS-CoV-2, National Institute for Health Research (Great Britain), Adenovirus diseases, Medical research, Humoral immunity, COVID-19, Meningococcal vaccines, Prevention of epidemics, Viral pneumonia, Research, Viral vaccines, Immunoglobulins, Immunization, Viruses, Nonopioid analgesics, Acetaminophen, Research methodology, Evaluation research, Medical cooperation, Comparative studies, Genes, Blind experiment, Research funding, Membrane proteins, Viral antibodies, T cells
Geographic Terms: Thames Valley (England), United Kingdom
Abstract: Background: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.Methods: We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.Findings: Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0·67 by Marburg VN; p<0·001).Interpretation: ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme.Funding: UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 145266344
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Folegatti%2C+Pedro+M%22&quot;&gt;Folegatti, Pedro M&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ewer%2C+Katie+J%22&quot;&gt;Ewer, Katie J&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aley%2C+Parvinder+K%22&quot;&gt;Aley, Parvinder K&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Angus%2C+Brian%22&quot;&gt;Angus, Brian&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Becker%2C+Stephan%22&quot;&gt;Becker, Stephan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Belij-Rammerstorfer%2C+Sandra%22&quot;&gt;Belij-Rammerstorfer, Sandra&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bellamy%2C+Duncan%22&quot;&gt;Bellamy, Duncan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bibi%2C+Sagida%22&quot;&gt;Bibi, Sagida&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bittaye%2C+Mustapha%22&quot;&gt;Bittaye, Mustapha&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Clutterbuck%2C+Elizabeth+A%22&quot;&gt;Clutterbuck, Elizabeth A&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dold%2C+Christina%22&quot;&gt;Dold, Christina&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Faust%2C+Saul+N%22&quot;&gt;Faust, Saul N&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Finn%2C+Adam%22&quot;&gt;Finn, Adam&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Flaxman%2C+Amy+L%22&quot;&gt;Flaxman, Amy L&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hallis%2C+Bassam%22&quot;&gt;Hallis, Bassam&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Heath%2C+Paul%22&quot;&gt;Heath, Paul&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jenkin%2C+Daniel%22&quot;&gt;Jenkin, Daniel&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lazarus%2C+Rajeka%22&quot;&gt;Lazarus, Rajeka&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Makinson%2C+Rebecca%22&quot;&gt;Makinson, Rebecca&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Minassian%2C+Angela+M%22&quot;&gt;Minassian, Angela M&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 8/15/2020, Vol. 396 Issue 10249, p467-478. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22SARS-CoV-2%22&quot;&gt;SARS-CoV-2&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22National+Institute+for+Health+Research+%28Great+Britain%29%22&quot;&gt;National Institute for Health Research (Great Britain)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adenovirus+diseases%22&quot;&gt;Adenovirus diseases&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+research%22&quot;&gt;Medical research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Humoral+immunity%22&quot;&gt;Humoral immunity&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22COVID-19%22&quot;&gt;COVID-19&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Meningococcal+vaccines%22&quot;&gt;Meningococcal vaccines&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Prevention+of+epidemics%22&quot;&gt;Prevention of epidemics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viral+pneumonia%22&quot;&gt;Viral pneumonia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research%22&quot;&gt;Research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viral+vaccines%22&quot;&gt;Viral vaccines&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Immunoglobulins%22&quot;&gt;Immunoglobulins&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Immunization%22&quot;&gt;Immunization&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viruses%22&quot;&gt;Viruses&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Nonopioid+analgesics%22&quot;&gt;Nonopioid analgesics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Acetaminophen%22&quot;&gt;Acetaminophen&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+methodology%22&quot;&gt;Research methodology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Evaluation+research%22&quot;&gt;Evaluation research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+cooperation%22&quot;&gt;Medical cooperation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Comparative+studies%22&quot;&gt;Comparative studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Genes%22&quot;&gt;Genes&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Blind+experiment%22&quot;&gt;Blind experiment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+funding%22&quot;&gt;Research funding&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Membrane+proteins%22&quot;&gt;Membrane proteins&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viral+antibodies%22&quot;&gt;Viral antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22T+cells%22&quot;&gt;T cells&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Thames+Valley+%28England%29%22&quot;&gt;Thames Valley (England)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22United+Kingdom%22&quot;&gt;United Kingdom&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.&lt;bold&gt;Methods: &lt;/bold&gt;We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 &#215; 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.&lt;bold&gt;Findings: &lt;/bold&gt;Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p&lt;0&#183;05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0&#183;67 by Marburg VN; p&lt;0&#183;001).&lt;bold&gt;Interpretation: &lt;/bold&gt;ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme.&lt;bold&gt;Funding: &lt;/bold&gt;UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland&#39;s NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gie&#223;en-Marburg-Langen. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=145266344
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(20)31604-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 467
    Subjects:
      – SubjectFull: SARS-CoV-2
        Type: general
      – SubjectFull: National Institute for Health Research (Great Britain)
        Type: general
      – SubjectFull: Adenovirus diseases
        Type: general
      – SubjectFull: Medical research
        Type: general
      – SubjectFull: Humoral immunity
        Type: general
      – SubjectFull: COVID-19
        Type: general
      – SubjectFull: Meningococcal vaccines
        Type: general
      – SubjectFull: Prevention of epidemics
        Type: general
      – SubjectFull: Viral pneumonia
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Viral vaccines
        Type: general
      – SubjectFull: Immunoglobulins
        Type: general
      – SubjectFull: Immunization
        Type: general
      – SubjectFull: Viruses
        Type: general
      – SubjectFull: Nonopioid analgesics
        Type: general
      – SubjectFull: Acetaminophen
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Genes
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Membrane proteins
        Type: general
      – SubjectFull: Viral antibodies
        Type: general
      – SubjectFull: T cells
        Type: general
      – SubjectFull: Thames Valley (England)
        Type: general
      – SubjectFull: United Kingdom
        Type: general
    Titles:
      – TitleFull: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Folegatti, Pedro M
      – PersonEntity:
          Name:
            NameFull: Ewer, Katie J
      – PersonEntity:
          Name:
            NameFull: Aley, Parvinder K
      – PersonEntity:
          Name:
            NameFull: Angus, Brian
      – PersonEntity:
          Name:
            NameFull: Becker, Stephan
      – PersonEntity:
          Name:
            NameFull: Belij-Rammerstorfer, Sandra
      – PersonEntity:
          Name:
            NameFull: Bellamy, Duncan
      – PersonEntity:
          Name:
            NameFull: Bibi, Sagida
      – PersonEntity:
          Name:
            NameFull: Bittaye, Mustapha
      – PersonEntity:
          Name:
            NameFull: Clutterbuck, Elizabeth A
      – PersonEntity:
          Name:
            NameFull: Dold, Christina
      – PersonEntity:
          Name:
            NameFull: Faust, Saul N
      – PersonEntity:
          Name:
            NameFull: Finn, Adam
      – PersonEntity:
          Name:
            NameFull: Flaxman, Amy L
      – PersonEntity:
          Name:
            NameFull: Hallis, Bassam
      – PersonEntity:
          Name:
            NameFull: Heath, Paul
      – PersonEntity:
          Name:
            NameFull: Jenkin, Daniel
      – PersonEntity:
          Name:
            NameFull: Lazarus, Rajeka
      – PersonEntity:
          Name:
            NameFull: Makinson, Rebecca
      – PersonEntity:
          Name:
            NameFull: Minassian, Angela M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 08
              Text: 8/15/2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 396
            – Type: issue
              Value: 10249
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1